{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:50:23Z","timestamp":1791931823177,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32425035"],"award-info":[{"award-number":["32425035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Municipal Science & Technology Commission, Administrative Commission of Zhongguancun Science Park","award":["No. Z221100007922017"],"award-info":[{"award-number":["No. Z221100007922017"]}]},{"name":"Neurofibromatosis Shenzhen Care Center"},{"name":"Beijing Institute for Stem Cell and Regenerative Medicine","award":["2023FH107"],"award-info":[{"award-number":["2023FH107"]}]},{"name":"Beijing Institute for Stem Cell and Regenerative Medicine","award":["2022FH122"],"award-info":[{"award-number":["2022FH122"]}]},{"name":"Beijing Institute for Stem Cell and Regenerative Medicine","award":["2023FH105"],"award-info":[{"award-number":["2023FH105"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-025-01965-6","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T09:59:11Z","timestamp":1740823151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development of CAR-T cell therapy for NF1\/SWN-related nerve sheath tumor treatment"],"prefix":"10.1186","volume":"13","author":[{"given":"Na","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beilei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2135-1769","authenticated-orcid":false,"given":"Haoyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"1965_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev.pathol.2.010506.091940","volume":"2","author":"AI McClatchey","year":"2007","unstructured":"McClatchey AI (2007) Neurofibromatosis. Annu Rev Pathol 2:191\u2013216. https:\/\/doi.org\/10.1146\/annurev.pathol.2.010506.091940","journal-title":"Annu Rev Pathol"},{"key":"1965_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115850","author":"R Tamura","year":"2021","unstructured":"Tamura R (2021) Current understanding of neurofibromatosis type 1, 2, and schwannomatosis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22115850","journal-title":"Int J Mol Sci"},{"key":"1965_CR3","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","volume":"23","author":"E Legius","year":"2021","unstructured":"Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, Blakeley J, Babovic-Vuksanovic D, Cunha KS, Ferner R et al (2021) Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 23:1506\u20131513. https:\/\/doi.org\/10.1038\/s41436-021-01170-5","journal-title":"Genet Med"},{"key":"1965_CR4","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.gim.2022.05.007","volume":"24","author":"SR Plotkin","year":"2022","unstructured":"Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, Babovic-Vuksanovic D, Ferner R, Fisher MJ, Friedman JM et al (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med 24:1967\u20131977. https:\/\/doi.org\/10.1016\/j.gim.2022.05.007","journal-title":"Genet Med"},{"key":"1965_CR5","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/gim.2017.215","volume":"20","author":"RA Kallionpaa","year":"2018","unstructured":"Kallionpaa RA, Uusitalo E, Leppavirta J, Poyhonen M, Peltonen S, Peltonen J (2018) Prevalence of neurofibromatosis type 1 in the Finnish population. Genet Med 20:1082\u20131086. https:\/\/doi.org\/10.1038\/gim.2017.215","journal-title":"Genet Med"},{"key":"1965_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cancergen.2014.04.001","volume":"207","author":"MJ Smith","year":"2014","unstructured":"Smith MJ, Wallace AJ, Bowers NL, Eaton H, Evans DG (2014) SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors. Cancer Genet 207:373\u2013378. https:\/\/doi.org\/10.1016\/j.cancergen.2014.04.001","journal-title":"Cancer Genet"},{"key":"1965_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41467-024-44755-9","volume":"15","author":"HN Vasudevan","year":"2024","unstructured":"Vasudevan HN, Payne E, Delley CL, John Liu S, Mirchia K, Sale MJ, Lastella S, Nunez MS, Lucas CG, Eaton CD et al (2024) Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. Nat Commun 15:477. https:\/\/doi.org\/10.1038\/s41467-024-44755-9","journal-title":"Nat Commun"},{"key":"1965_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s40265-020-01331-x","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A, Keam SJ (2020) Selumetinib: first approval. Drugs 80:931\u2013937. https:\/\/doi.org\/10.1007\/s40265-020-01331-x","journal-title":"Drugs"},{"key":"1965_CR9","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B (2023) From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol 14:1188049. https:\/\/doi.org\/10.3389\/fimmu.2023.1188049","journal-title":"Front Immunol"},{"key":"1965_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, Cherif H, Uddin S, Steinhoff M, Marincola FM et al (2023) CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer 22:20. https:\/\/doi.org\/10.1186\/s12943-023-01723-z","journal-title":"Mol Cancer"},{"key":"1965_CR11","doi-asserted-by":"publisher","unstructured":"Shin MH, Oh E, Kim Y, Nam DH, Jeon SY, Yu JH, Minn D (2023) Recent advances in CAR-based solid tumor immunotherapy. Cells. https:\/\/doi.org\/10.3390\/cells12121606","DOI":"10.3390\/cells12121606"},{"key":"1965_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK (2019) CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol 10:128. https:\/\/doi.org\/10.3389\/fimmu.2019.00128","journal-title":"Front Immunol"},{"key":"1965_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick K, O\u2019Brien S, Moon E, Albelda SM (2017) CAR T cell therapy for solid tumors. Annu Rev Med 68:139\u2013152. https:\/\/doi.org\/10.1146\/annurev-med-062315-120245","journal-title":"Annu Rev Med"},{"key":"1965_CR14","unstructured":"NATIONAL CANCER INSTITUTE Division of Cancer Epidemiology Genetics. Neurofibromatosis Type 1 and Cancer Susceptibility. https:\/\/dceg.cancer.gov\/research\/what-we-study\/neurofibromatosis-cancer-risk"},{"key":"1965_CR15","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1474-4422(22)00261-7","volume":"21","author":"ZC Wang","year":"2022","unstructured":"Wang ZC, Li HB, Wei CJ, Wang W, Li QF (2022) Community-boosted neurofibromatosis research in China. Lancet Neurol 21:773\u2013774. https:\/\/doi.org\/10.1016\/S1474-4422(22)00261-7","journal-title":"Lancet Neurol"},{"key":"1965_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/cns-2016-0024","volume":"6","author":"S Karmakar","year":"2017","unstructured":"Karmakar S, Reilly KM (2017) The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. CNS Oncol 6:45\u201360. https:\/\/doi.org\/10.2217\/cns-2016-0024","journal-title":"CNS Oncol"},{"key":"1965_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11060-018-2788-6","volume":"138","author":"S Wang","year":"2018","unstructured":"Wang S, Liechty B, Patel S, Weber JS, Hollmann TJ, Snuderl M, Karajannis MA (2018) Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol 138:183\u2013190. https:\/\/doi.org\/10.1007\/s11060-018-2788-6","journal-title":"J Neurooncol"},{"key":"1965_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1267\/ahc.11027","volume":"44","author":"N Song","year":"2011","unstructured":"Song N, Liu J, An S, Nishino T, Hishikawa Y, Koji T (2011) Immunohistochemical analysis of histone H3 modifications in germ cells during mouse spermatogenesis. Acta Histochem Cytochem 44:183\u2013190. https:\/\/doi.org\/10.1267\/ahc.11027","journal-title":"Acta Histochem Cytochem"},{"key":"1965_CR19","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/labinvest.3700675","volume":"87","author":"GQ Perrin","year":"2007","unstructured":"Perrin GQ, Li H, Fishbein L, Thomson SA, Hwang MS, Scarborough MT, Yachnis AT, Wallace MR, Mareci TH, Muir D (2007) An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation. Lab Invest 87:1092\u20131102. https:\/\/doi.org\/10.1038\/labinvest.3700675","journal-title":"Lab Invest"},{"key":"1965_CR20","doi-asserted-by":"publisher","unstructured":"Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, Wei XF, Han W, Wang H (2020) TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.133977","DOI":"10.1172\/jci.insight.133977"},{"key":"1965_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s13238-018-0605-9","volume":"10","author":"W Mu","year":"2019","unstructured":"Mu W, Tang N, Cheng C, Sun W, Wei X, Wang H (2019) In vitro transcribed sgRNA causes cell death by inducing interferon release. Protein Cell 10:461\u2013465. https:\/\/doi.org\/10.1007\/s13238-018-0605-9","journal-title":"Protein Cell"},{"key":"1965_CR22","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman EK, Chen T, Amendola M, van Steensel B (2014) Easy quantitative assessment of genome editing by sequence trace decomposition. Nucl Acids Res 42:e168. https:\/\/doi.org\/10.1093\/nar\/gku936","journal-title":"Nucl Acids Res"},{"key":"1965_CR23","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1038\/s41467-019-13640-1","volume":"10","author":"R Tamura","year":"2019","unstructured":"Tamura R, Fujioka M, Morimoto Y, Ohara K, Kosugi K, Oishi Y, Sato M, Ueda R, Fujiwara H, Hikichi T et al (2019) A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2. Nat Commun 10:5758. https:\/\/doi.org\/10.1038\/s41467-019-13640-1","journal-title":"Nat Commun"},{"key":"1965_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ccr.2004.10.016","volume":"7","author":"BC Ling","year":"2005","unstructured":"Ling BC, Wu J, Miller SJ, Monk KR, Shamekh R, Rizvi TA, Decourten-Myers G, Vogel KS, DeClue JE, Ratner N (2005) Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 7:65\u201375. https:\/\/doi.org\/10.1016\/j.ccr.2004.10.016","journal-title":"Cancer Cell"},{"key":"1965_CR25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s11060-018-2922-5","volume":"139","author":"DS Osorio","year":"2018","unstructured":"Osorio DS, Hu J, Mitchell C, Allen JC, Stanek J, Hagiwara M, Karajannis MA (2018) Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2. J Neurooncol 139:749\u2013755. https:\/\/doi.org\/10.1007\/s11060-018-2922-5","journal-title":"J Neurooncol"},{"key":"1965_CR26","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.2353\/ajpath.2006.050859","volume":"168","author":"J Wu","year":"2006","unstructured":"Wu J, Crimmins JT, Monk KR, Williams JP, Fitzgerald ME, Tedesco S, Ratner N (2006) Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma. Am J Pathol 168:1686\u20131696. https:\/\/doi.org\/10.2353\/ajpath.2006.050859","journal-title":"Am J Pathol"},{"key":"1965_CR27","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1172\/jci7610","volume":"105","author":"JE DeClue","year":"2000","unstructured":"DeClue JE, Heffelfinger S, Benvenuto G, Ling B, Li S, Rui W, Vass WC, Viskochil D, Ratner N (2000) Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 105:1233\u20131241. https:\/\/doi.org\/10.1172\/jci7610","journal-title":"J Clin Invest"},{"key":"1965_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.tripleo.2011.04.019","volume":"113","author":"M Blessmann","year":"2012","unstructured":"Blessmann M, Gr\u00f6be A, Quaas A, Kaifi JT, Mistakidis G, Bernreuther C, Sauter G, Gros S, Rawnaq T, Friedrich R et al (2012) Adhesion molecule L1 is down-regulated in malignant peripheral nerve sheath tumors versus benign neurofibromatosis type 1-associated tumors. Oral Surg Oral Med Oral Pathol Oral Radiol 113:239\u2013244. https:\/\/doi.org\/10.1016\/j.tripleo.2011.04.019","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1965_CR29","doi-asserted-by":"publisher","unstructured":"Inaguma S, Wang Z, Lasota JP, Miettinen MM (2016) Expression of neural cell adhesion molecule L1 (CD171) in neuroectodermal and other tumors: an immunohistochemical study of 5155 tumors and critical evaluation of CD171 prognostic value in gastrointestinal stromal tumors. Oncotarget 7:55276\u201355289. https:\/\/doi.org\/10.18632\/oncotarget.10527","DOI":"10.18632\/oncotarget.10527"},{"key":"1965_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1476-4598-3-20","volume":"3","author":"P L\u00e9vy","year":"2004","unstructured":"L\u00e9vy P, Vidaud D, Leroy K, Laurendeau I, Wechsler J, Bolasco G, Parfait B, Wolkenstein P, Vidaud M, Bi\u00e8che I (2004) Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. Mol Cancer 3:20. https:\/\/doi.org\/10.1186\/1476-4598-3-20","journal-title":"Mol Cancer"},{"key":"1965_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1750-3639.2004.tb00067.x","volume":"14","author":"MA Watson","year":"2004","unstructured":"Watson MA, Perry A, Tihan T, Prayson RA, Guha A, Bridge J, Ferner R, Gutmann DH (2004) Gene expression profiling reveals unique molecular subtypes of neurofibromatosis type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol 14:297\u2013303. https:\/\/doi.org\/10.1111\/j.1750-3639.2004.tb00067.x","journal-title":"Brain Pathol"},{"key":"1965_CR32","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","volume":"22","author":"Y Liu","year":"2020","unstructured":"Liu Y, Guo Y, Wu Z, Feng K, Tong C, Wang Y, Dai H, Shi F, Yang Q, Han W (2020) Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial. Cytotherapy 22:573\u2013580. https:\/\/doi.org\/10.1016\/j.jcyt.2020.04.088","journal-title":"Cytotherapy"},{"key":"1965_CR33","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","volume":"147","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang Z, Ding Y, Fang Y, Wang P, Chu W, Jin Z, Yang X, Wang J, Lou J et al (2021) Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients. J Cancer Res Clin Oncol 147:3725\u20133734. https:\/\/doi.org\/10.1007\/s00432-021-03613-7","journal-title":"J Cancer Res Clin Oncol"},{"key":"1965_CR34","first-page":"1434","volume":"11","author":"R Dienstmann","year":"2010","unstructured":"Dienstmann R, Tabernero J (2010) Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. Curr Opin Investig Drugs 11:1434\u20131441","journal-title":"Curr Opin Investig Drugs"},{"key":"1965_CR35","doi-asserted-by":"publisher","first-page":"30375","DOI":"10.1074\/jbc.M401218200","volume":"279","author":"TG Johns","year":"2004","unstructured":"Johns TG, Adams TE, Cochran JR, Hall NE, Hoyne PA, Olsen MJ, Kim YS, Rothacker J, Nice EC, Walker F et al (2004) Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 279:30375\u201330384. https:\/\/doi.org\/10.1074\/jbc.M401218200","journal-title":"J Biol Chem"},{"key":"1965_CR36","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/sj.bjc.6602470","volume":"92","author":"C Panousis","year":"2005","unstructured":"Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee FT, Wang D, Gan H, Cao D et al (2005) Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br J Cancer 92:1069\u20131077. https:\/\/doi.org\/10.1038\/sj.bjc.6602470","journal-title":"Br J Cancer"},{"key":"1965_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74\u201380. https:\/\/doi.org\/10.1126\/science.aaa6204","journal-title":"Science"},{"key":"1965_CR38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nri3902","volume":"15","author":"SJ Turley","year":"2015","unstructured":"Turley SJ, Cremasco V, Astarita JL (2015) Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol 15:669\u2013682. https:\/\/doi.org\/10.1038\/nri3902","journal-title":"Nat Rev Immunol"},{"key":"1965_CR39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.it.2010.04.002","volume":"31","author":"L Yang","year":"2010","unstructured":"Yang L, Pang Y, Moses HL (2010) TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31:220\u2013227. https:\/\/doi.org\/10.1016\/j.it.2010.04.002","journal-title":"Trends Immunol"},{"key":"1965_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050470","author":"J Kondo","year":"2019","unstructured":"Kondo J, Inoue M (2019) Application of cancer organoid model for drug screening and personalized therapy. Cells. https:\/\/doi.org\/10.3390\/cells8050470","journal-title":"Cells"},{"key":"1965_CR41","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/neuonc\/noq012","volume":"12","author":"S Ammoun","year":"2010","unstructured":"Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO, Karajannis MA (2010) ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol 12:834\u2013843. https:\/\/doi.org\/10.1093\/neuonc\/noq012","journal-title":"Neuro Oncol"},{"key":"1965_CR42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00401-004-0875-6","volume":"108","author":"U Andersson","year":"2004","unstructured":"Andersson U, Guo D, Malmer B, Bergenheim AT, Br\u00e4nnstr\u00f6m T, Hedman H, Henriksson R (2004) Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 108:135\u2013142. https:\/\/doi.org\/10.1007\/s00401-004-0875-6","journal-title":"Acta Neuropathol"},{"key":"1965_CR43","doi-asserted-by":"publisher","unstructured":"Castellsagu\u00e9 J, Gel B, Fern\u00e1ndez-Rodr\u00edguez J, Llatj\u00f3s R, Blanco I, Benavente Y, P\u00e9rez-Sidelnikova D, Garc\u00eda-Del Muro J, Vi\u00f1als JM, Vidal A et al (2015) Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. EMBO Mol Med 7:608\u2013627. https:\/\/doi.org\/10.15252\/emmm.201404430","DOI":"10.15252\/emmm.201404430"},{"key":"1965_CR44","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/path.5908","volume":"257","author":"F Zhao","year":"2022","unstructured":"Zhao F, Chen Y, Li SW, Zhang J, Zhang S, Zhao XB, Yang ZJ, Wang B, He QY, Wang LM et al (2022) Novel patient-derived xenograft and cell line models for therapeutic screening in NF2-associated schwannoma. J Pathol 257:620\u2013634. https:\/\/doi.org\/10.1002\/path.5908","journal-title":"J Pathol"},{"key":"1965_CR45","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/neuonc\/noab273","volume":"24","author":"KG Abdullah","year":"2022","unstructured":"Abdullah KG, Bird CE, Buehler JD, Gattie LC, Savani MR, Sternisha AC, Xiao Y, Levitt MM, Hicks WH, Li W et al (2022) Establishment of patient-derived organoid models of lower-grade glioma. Neuro Oncol 24:612\u2013623. https:\/\/doi.org\/10.1093\/neuonc\/noab273","journal-title":"Neuro Oncol"},{"key":"1965_CR46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-022-01278-4","volume":"15","author":"H Xu","year":"2022","unstructured":"Xu H, Jiao D, Liu A, Wu K (2022) Tumor organoids: applications in cancer modeling and potentials in precision medicine. J Hematol Oncol 15:58. https:\/\/doi.org\/10.1186\/s13045-022-01278-4","journal-title":"J Hematol Oncol"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-01965-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-01965-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-01965-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T09:59:23Z","timestamp":1740823163000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-025-01965-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1965"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-01965-6","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"31 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}